Literature DB >> 20025960

Rapid diagnosis of spinal muscular atrophy using tetra-primer ARMS PCR assay: simultaneous detection of SMN1 and SMN2 deletion.

Ibrahim Baris1, Ozdal Etlik, Vedat Koksal, S Tugba Arican-Baris.   

Abstract

Spinal muscular atrophy (SMA), the leading genetic cause of death in childhood, is an autosomal recessive neuromuscular disorder characterized by progressive muscle weakness, associated with deletions of the survival motor neuron 1 (SMN1) gene. Approximately 94% of SMA patients carry homologous deletions of SMN1 exon(s) 7 (and 8). Because of the high incidence and severity of the disease, precise detection and quantification of SMN1 and SMN2 gene copy numbers is essential for diagnosis and genetic counseling. We have developed a reliable single-tube tetra-primer PCR assay to simultaneously detect both the SMN1 and SMN2 exon 7 deletion using the advantage of C/T difference at nucleotide position of 840 in exon 7. The assay has been optimized and tested in 48 healthy controls, 20 known patients with SMA, 12 carriers (one SMN1 copy), and 8 amniotic fluids suspected of having SMA for whom we had determined the SMN1/SMN2 deletion by an additional PCR-RFLP method. We have observed complete concordance between methods. Our tetra-primer PCR assay is sensitive, low-cost, and easy to use method for simultaneous detection of both SMN1 and SMN2 deletion, which could be used even in "low-tech" laboratories.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20025960     DOI: 10.1016/j.mcp.2009.12.001

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  2 in total

1.  Guidelines for the tetra-primer ARMS-PCR technique development.

Authors:  Ruan Felipe Vieira Medrano; Camila Andréa de Oliveira
Journal:  Mol Biotechnol       Date:  2014-07       Impact factor: 2.695

2.  Rapid molecular diagnosis of spinal muscular atrophy.

Authors:  Balraj Mittal
Journal:  Indian J Med Res       Date:  2012       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.